| Grant ID | DP240243 |
| Awarded On | May 15, 2024 |
| Title | Phase 1 Trial of Highly Potent Allogeneic G-NK Cells for Treatment of Multiple Myeloma and Non- Hodgkin's Lymphoma |
| Program | Product Development Research |
| Award Mechanism | Texas Therapeutics Company Awards for Product Development Research |
| Institution/Organization | Indapta Therapeutics |
| Principal Investigator/Program Director | Mark Frohlich |
| Cancer Sites | Lymphoma, Myeloma |
| Contracted Amount |
$4,500,000* *Pending contract negotiation |
| Lay Summary |
This study focuses on an allogeneic cellular immunotherapy to treat cancer. Indapta, a Houston-based biotech company, has identified a highly potent subset of natural killer (NK) cells, g-NK cells, that it can expand from healthy donors. Indapta's g-NK product, IDP-023, has great potential to be a significant medical breakthrough in treating patients with advanced non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) who have few therapeutic options and are not candidates for autologous cellular therapy. Recent approved treatments (CAR-T, T cell engagers) have limitations: lack of durability, significant toxicities, and manufacturing delays. IDP-023 is an "off-the-shelf" cryopreserved pro... |